Evidence map›Paper›PMID 31652593›Full record

ReviewMolecules (Basel, Switzerland)2019

Promising Approach in the Treatment of Glaucoma Using Nanotechnology and Nanomedicine-Based Systems.

Fidiniaina Rina Juliana, Samuel Kesse, Kofi Oti Boakye-Yiadom, Hanitrarimalala Veroniaina, Huihui Wang, Meihao Sun

Open access · goldAbstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 39 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fidiniaina Rina JulianaCollege of Chemistry and Life Sciences, Zhejiang Normal University, Jinhua 321004, China. younitra@gmail.com.
Samuel KesseSchool of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China. kessejnr@yahoo.com.ORCID 0000-0002-6510-325X
Kofi Oti Boakye-YiadomSchool of Pharmacy, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China. otiboakye1000@gmail.com.
Hanitrarimalala VeroniainaState Key Laboratory of Modern Chinese Medicine, China Pharmaceutical University, Nanjing 210009, China. scholarha@yahoo.com.
Huihui WangCollege of Chemistry and Life Sciences, Zhejiang Normal University, Jinhua 321004, China. sanket.acharya4@gmail.com.
Meihao SunCollege of Chemistry and Life Sciences, Zhejiang Normal University, Jinhua 321004, China. mhsun@zjnu.cn.
China Pharmaceutical University · CNZhejiang Normal University · CN

Funding

Chinese Government Scholarship 2016288010
6 · The paper itself

Abstract

Glaucoma is considered a leading cause of blindness with the human eye being one of the body's most delicate organs. Ocular diseases encompass diverse diseases affecting the anterior and posterior ocular sections, respectively. The human eye's peculiar and exclusive anatomy and physiology continue to pose a significant obstacle to researchers and pharmacologists in the provision of efficient drug delivery. Though several traditional invasive and noninvasive eye therapies exist, including implants, eye drops, and injections, there are still significant complications that arise which may either be their low bioavailability or the grave ocular adverse effects experienced thereafter. On the other hand, new nanoscience technology and nanotechnology serve as a novel approach in ocular disease treatment. In order to interact specifically with ocular tissues and overcome ocular challenges, numerous active molecules have been modified to react with nanocarriers. In the general population of glaucoma patients, disease growth and advancement cannot be contained by decreasing intraocular pressure (IOP), hence a spiking in future research for novel drug delivery systems and target therapeutics. This review focuses on nanotechnology and its therapeutic and diagnostic prospects in ophthalmology, specifically glaucoma. Nanotechnology and nanomedicine history, the human eye anatomy, research frontiers in nanomedicine and nanotechnology, its imaging modal quality, diagnostic and surgical approach, and its possible application in glaucoma will all be further explored below. Particular focus will be on the efficiency and safety of this new therapy and its advances.

Indexed as

AnimalsBiological AvailabilityDrug Delivery SystemsDrug ImplantsDrug LiberationGlaucomaHumansIntraocular PressureMiceNanomedicineRabbitsTomography, Optical CoherenceTrabecular MeshworkDrug Implantsdrug deliveryglaucomaimagingintraocular pressureMEMsnanomedicinenanotechnology

Identifiers

PMID31652593
PMCPMC6833088
OpenAlexW2981787223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.